Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia

E-ISSN： 1365-2141|169|6|768-776

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.6, 2015-06, pp. : 768-776

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Half‐life extended factor VIII for the treatment of hemophilia A

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S176-S179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 210-218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transition considerations for extended half‐life factor products

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 285-288

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 300-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Gringeri et al.: ‘recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling’

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : e489-e492

John Wiley & Sons Inc

Access to resources Recommend Favorite